Select Page

In recent days, my inbox has been overflowing with emails from you regarding this afternoon’s business update from Cue Biopharma, Inc. (CUE).

Cue is the most compelling biotech in the market right now. So like parents waiting for the birth of a new baby, everyone’s wondering what will be “delivered.” 

Many of you are questioning if bad news is coming. But there’s no such thing as an ugly baby, right?

In all seriousness, there’s no reason to expect anything but good news today. Management wouldn’t have scheduled an interim call to deliver bad news. Just saying.

It’s just a matter of how good the news/data is this afternoon that will determine how quickly the rest of Wall Street wakes up to the blockbuster and multi-billion dollar potential here.

With that in mind, I decided to jump in front of the camera without getting all gussied up to share my reasonable expectations for today. 

Check it out by clicking on the image below.

This content is reserved for subscribers. But for a limited time only you can use Coupon Code DTR2022 to subscribe at the lowest price we’ve ever offered for an annual subscription.